<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03061500</url>
  </required_header>
  <id_info>
    <org_study_id>PI2289</org_study_id>
    <nct_id>NCT03061500</nct_id>
  </id_info>
  <brief_title>Prognostic Value of Proadrenomedullin in Intra-abdominal Sepsis</brief_title>
  <official_title>Proadrenomedullin as a Severity Score and Prognostic Marker in Intra-abdominal Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Investigación Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto de Investigación Hospital Universitario La Paz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An observational, prospective study whose main objective is to measure the value of&#xD;
      Pro-adrenomedullin as a prognostic marker and predictor of mortality in patients with&#xD;
      intra-abdominal sepsis after damage control surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Proadrenomedullin as a Severity Score and Prognostic Marker in Intra-abdominal Sepsis&#xD;
&#xD;
      Research Type:&#xD;
&#xD;
      Prospective, observational study.&#xD;
&#xD;
      Duration:&#xD;
&#xD;
      October 2016 - October 2017&#xD;
&#xD;
      Associated Medical Centers:&#xD;
&#xD;
      La Paz University Hospital (Madrid), La Princesa Hospital (Madrid), Hospital del Mar&#xD;
      (Barcelona), Hospital Clínico de Valladolid and Hospital Clínico de Valencia.&#xD;
&#xD;
      Main Goal:&#xD;
&#xD;
      To measure the value of Pro-adrenomedullin as a prognostic marker and predictor of mortality&#xD;
      in patients with intra-abdominal sepsis after damage control surgery.&#xD;
&#xD;
      Secondary Goals:&#xD;
&#xD;
      Make a comparison with other biomarkers (procalcitonin, lactic acid, CRP) and clinical&#xD;
      severity scales used in standard critical practice (SAPSII, SOFA).&#xD;
&#xD;
      To establish a correlation between the levels of Pro-Adrenomedullin, the time of stay in&#xD;
      critical care units, days of mechanical ventilation and mortality.&#xD;
&#xD;
      Variables:&#xD;
&#xD;
      A. Demographics&#xD;
&#xD;
      B. Date of admission to hospital and date of admission to critical care unit unit&#xD;
&#xD;
      C. Clinical data:&#xD;
&#xD;
        -  Associated diseases&#xD;
&#xD;
        -  SAPS II&#xD;
&#xD;
        -  SOFA&#xD;
&#xD;
      D. Intra-abdominal infection episode data&#xD;
&#xD;
        -  Systemic response: sepsis / septic shock&#xD;
&#xD;
        -  Isolated microorganisms in blood cultures and intra-abdominal fluid&#xD;
&#xD;
        -  Complications related to the infectious process (ARDS, need for mechanical ventilation,&#xD;
           vasopressors, disseminated intravascular coagulation, acute renal failure, renal&#xD;
           replacement techniques)&#xD;
&#xD;
      E. Follow-up&#xD;
&#xD;
        -  Critical unit registration date&#xD;
&#xD;
        -  Date of discharge from hospital&#xD;
&#xD;
        -  Critical unit mortality, in-hospital mortality and 30 days mortality (assessed by&#xD;
           telephone contact if the patient had been discharged).&#xD;
&#xD;
      F. Pro-adrenomedullin levels at admission, 24 and 72 hours. As well as procalcitonin (PCT),&#xD;
      lactic acid and polymerase Chain Reaction (PCR) levels.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">October 15, 2016</start_date>
  <completion_date type="Anticipated">October 15, 2017</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>mortality</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>days of stay in critical units</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>days of mechanical ventilation</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>days of need vasopressors</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>days of need for renal replacement techniques</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Intraabdominal Infections</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Intraabdominal sepsis patients after damage control surgery&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients consecutively collected, adults over 18, who are admitted to critical&#xD;
             care unit with the diagnosis of localized or generalized intraabdominal infection&#xD;
             after damage control surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Patients with neutropenia induced by bone marrow transplant or by chemotherapy (&lt;500&#xD;
             neutrophils / ml).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ana Maria Montero Feijoo</last_name>
    <phone>+34696079362</phone>
    <email>anamonterofeijoo@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario de la Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Maria Montero Feijoo</last_name>
      <phone>+34696079362</phone>
      <email>anamonterofeijoo@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>España PP, Capelastegui A, Mar C, Bilbao A, Quintana JM, Diez R, Esteban C, Bereciartua E, Unanue U, Uranga A. Performance of pro-adrenomedullin for identifying adverse outcomes in community-acquired pneumonia. J Infect. 2015 May;70(5):457-66. doi: 10.1016/j.jinf.2014.12.003. Epub 2014 Dec 11.</citation>
    <PMID>25499199</PMID>
  </reference>
  <reference>
    <citation>Bello S, Lasierra AB, Mincholé E, Fandos S, Ruiz MA, Vera E, de Pablo F, Ferrer M, Menendez R, Torres A. Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology. Eur Respir J. 2012 May;39(5):1144-55. doi: 10.1183/09031936.00080411. Epub 2011 Nov 10.</citation>
    <PMID>22075489</PMID>
  </reference>
  <reference>
    <citation>Cavallazzi R, El-Kersh K, Abu-Atherah E, Singh S, Loke YK, Wiemken T, Ramirez J. Midregional proadrenomedullin for prognosis in community-acquired pneumonia: a systematic review. Respir Med. 2014 Nov;108(11):1569-80. Review.</citation>
    <PMID>25448309</PMID>
  </reference>
  <reference>
    <citation>Suberviola B, Castellanos-Ortega A, Llorca J, Ortiz F, Iglesias D, Prieto B. Prognostic value of proadrenomedullin in severe sepsis and septic shock patients with community-acquired pneumonia. Swiss Med Wkly. 2012 Mar 19;142:w13542. doi: 10.4414/smw.2012.13542. eCollection 2012.</citation>
    <PMID>22430899</PMID>
  </reference>
  <reference>
    <citation>Christ-Crain M, Morgenthaler NG, Struck J, Harbarth S, Bergmann A, Müller B. Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study. Crit Care. 2005;9(6):R816-24. Epub 2005 Nov 15.</citation>
    <PMID>16356231</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>February 19, 2017</study_first_submitted>
  <study_first_submitted_qc>February 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>February 19, 2017</last_update_submitted>
  <last_update_submitted_qc>February 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario La Paz</investigator_affiliation>
    <investigator_full_name>Ana María Montero Fijoo</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Proadrenomedullin</keyword>
  <keyword>Sepsis</keyword>
  <keyword>Intraabdominal Infections</keyword>
  <keyword>prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Intraabdominal Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

